prikaz prve stranice dokumenta Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke
  Download
PDF 418.32 KB
master's thesis
Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke
Split: University of Split, School of Medicine, 2018. urn:nbn:hr:171:044819
Čikeš, Karla
University of Split
School of Medicine
Pathology

Institutional repository: MEFST Repository

Cite this document

Čikeš, K. (2018). Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:044819

Čikeš, Karla. "Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke." Master's thesis, University of Split, School of Medicine, 2018. https://urn.nsk.hr/urn:nbn:hr:171:044819

Čikeš, Karla. "Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke." Master's thesis, University of Split, School of Medicine, 2018. https://urn.nsk.hr/urn:nbn:hr:171:044819

Čikeš, K. (2018). 'Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke', Master's thesis, University of Split, School of Medicine, accessed 05 November 2024, https://urn.nsk.hr/urn:nbn:hr:171:044819

Čikeš K. Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke [Master's thesis]. Split: University of Split, School of Medicine; 2018 [cited 2024 November 05] Available at: https://urn.nsk.hr/urn:nbn:hr:171:044819

K. Čikeš, "Procjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke", Master's thesis, University of Split, School of Medicine, Split, 2018. Available at: https://urn.nsk.hr/urn:nbn:hr:171:044819

Metadata
TitleProcjena kompletnog patološkog odgovora nakon neoadjuvantnog liječenja karcinoma dojke
Title (english)Asessment of complete pathological response after neoadjuvant treatment of breast cancer
AuthorKarla Čikeš
MentorIvana Mrklić (mentor)
Committee memberValdi Pešutić-Pisac (predsjednik povjerenstva)
Committee memberŽeljko Šundov (član povjerenstva)
Committee memberZenon Pogorelić (član povjerenstva)
GranterUniversity of Split
School of Medicine
(Pathology)
Split
Defense date and country2018, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Abstract
CILJ ISTRAŽIVANJA: Osnovni cilj ovog istraživanja bio je utvrditi razinu podudarnosti kliničko-patoloških značajki tumora, kao što su: veličina tumora, gradus tumora, ekspresija ER i PR, HER2/neu status i proliferacijski indeks prije i nakon primjene neoadjuvantne terapije, te utvrditi utjecaj imunofenotipa i gradusa tumora na stupanj odgovora na neoadjuvantu terapiju. MATERIJAL I METODE: U istraživanje je bilo uključeno 35 žena oboljelih od karcinoma dojke kod kojih je završeno neoadjuvantno liječenje u razdoblju od 1.1.2015. do 1.3.2018., a za koje su bili dostupni patohistološki nalazi prije i nakon neoadjuvantne terapije. Uvidom u medicinsku dokumentaciju Kliničkog zavoda za patologiju, sudsku medicinu i citologiju KBC-a Split izvađeni su podaci o dobi bolesnica, veličini tumora, histološkom tipu tumora, gradusu, limfovaskularnoj invaziji, statusu hormonskih receptora, HER 2/neu statusu i proliferacijskom indeksu. Za usporedbu ispitivanih varijabli korišteni su χ2-test te Wilcoxonov test. REZULTATI: Potpuni patološki odgovor na NAT su postigli tumori luminalnog B imunofenotipa s HER2 pozitivnim statusom te tumor iz HER2 pozitivne podskupine. Svi tumori koji su pokazali potpuni patološki odgovor na primjenu NAT bili su visokog histološkog gradusa. Mitotski indeks, ukupni gradus, veličina tumora te proliferacijski indeks nakon primjene NAT-a su bili značajno niži. Kod tri tumora zabilježena je promjena statusa PR, a kod dva promjena HER2 statusa nakon NAT-a. ZAKLJUČCI: Najbolji odgovor na neoadjuvantnu terapiju su imali tumori s pozitivnim HER2 statusom, te tumori višeg gradusa. Nakon primljene neoadjuvantne terapije došlo je do statistički značajnog smanjenja mitotskog indeksa, ukupnog gradusa, veličine tumora i proliferacijskog indeksa, te razlike u ekspresiji PR i HER2 statusa u resekcijskim uzorcima. S obzirom da se ekspresija tumorskih biomarkera može promijeniti nakon primjene kemoterapije, preporuča se testiranje ponoviti na resekcijskim uzorcima tkiva.
Abstract (english)
OBJECTIVES: The main purpose of this study was to determine the level of correlation of clinical pathological characteristics such as tumor size, tumor grade, ER and PR expression, HER2 status and proliferation index before and after neoadjuvant therapy, and to determine the effect of immunophenotype and grade on tumor response to neoadjuvant therapy. PATIENTS AND METHODS: The study included 35 women with breast cancer who completed neoadjuvant treatment in the period from Febrauary 2015. till March 2018., for whom pathohistological findings were available before and after neoadjuvant therapy. The age of the patient, tumor size, histological type, grade, lymphovascular invasion, hormone receptor status, HER2 status and proliferation index were taken from the medical documentation of the Department of Pathology, Cytology and Forensic Medicine, University Hospital Split. For comparison of the examined variables, χ2-test and Wilcoxon test were used. RESULTS: Complete pathological response to NAT was achieved by tumors with luminal B immunophenotype which were HER2 positive and tumor from HER2 positive subgroup. All tumors that showed complete pathological response to NAT were hystological grade III. The mitotic index, total grade, tumor size, and proliferation index after NAT were significantly lower. For three tumors PR status and HER2 status changed after NAT. CONCLUSION: The best response to neoadjuvant therapy was seen among HER2 positive tumors and tumors with higher grade. After receiving neoadjuvant therapy tumors showed a statistically significant decrease in mitotic index, total grade, tumor size, proliferation index and difference in PR expression and HER2 status. Since the expression of tumor biomarkers may change after neoadjuvant therapy, it is recommended to repeat the testing on a tissue resection samples.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:044819
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2018-10-22 10:58:36